Oncology drug company begins trading with a bang |
![]() |
![]() |
By Staff and Wire Reports |
Tuesday, 03 November 2009 20:03 |
![]()
San Antonio-based GenSpera will proceed with a Phase I clinical study during the fourth quarter of 2009 at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University in Baltimore and the University of Wisconsin Carbone Cancer Center in Madison. In preclinical testing, G-202 was shown to ablate tumors in animal models of breast cancer, prostate cancer and kidney cancer. The company’s second drug candidate, G-115, will directly target prostate cancer. "Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'. Add this page to your favorite Social Bookmarking websites ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |